Patents by Inventor Atsushi Takatori

Atsushi Takatori has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alkylating agent for alkylating target with driver oncogene mutation
    Patent number: 11185593
    Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: November 30, 2021
    Assignee: CHIBA PREFECTURE
    Inventors: Hiroki Nagase, Hiroshi Sugiyama, Toshikazu Bando, Atsushi Takatori
  • NOVEL ALKYLATING AGENT FOR ALKYLATING TARGET WITH DRIVER ONCOGENE MUTATION
    Publication number: 20200376133
    Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.
    Type: Application
    Filed: July 1, 2020
    Publication date: December 3, 2020
    Applicant: Chiba Prefecture
    Inventors: Hiroki NAGASE, Hiroshi SUGIYAMA, Toshikazu BANDO, Atsushi TAKATORI
  • Alkylating agent for alkylating target with driver oncogene mutation
    Patent number: 10751421
    Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: August 25, 2020
    Assignee: CHIBA PREFECTURE
    Inventors: Hiroki Nagase, Hiroshi Sugiyama, Toshikazu Bando, Atsushi Takatori
  • NOVEL ALKYLATING AGENT
    Publication number: 20190262457
    Abstract: An object of the present invention is to provide a novel alkylating agent that specifically binds to an immune checkpoint gene to induce cell death, and has tumor-specific accumulating properties. The present invention provides a conjugate comprising an alkylating agent bonded to a polyamide that specifically binds to a gene encoding an immune checkpoint molecule, an alkylating agent specific for a gene encoding an immune checkpoint molecule, comprising the conjugate, and a pharmaceutical composition comprising the conjugate.
    Type: Application
    Filed: September 21, 2017
    Publication date: August 29, 2019
    Applicant: CHIBA-PREFECTURE
    Inventors: Hiroki NAGASE, Asuka HATTORI, Takayoshi WATANABE, Atsushi TAKATORI
  • METHOD FOR SCREENING OF THERAPEUTIC AGENT FOR CANCER
    Publication number: 20110124006
    Abstract: A screening method for a therapeutic agent for cancer, the method including: a step of measuring an interaction between NLRR1 and EGFR under each condition of being in the presence of a test substance and in the absence of a test substance; and a step of determining that the test substance is a therapeutic agent for cancer when the interaction between NLRR1 and EGFR in the presence of the test substance is weaker than the interaction between NLRR1 and EGFR in the absence of the test substance.
    Type: Application
    Filed: February 27, 2009
    Publication date: May 26, 2011
    Applicant: Hismitsu Pharmaceutical Co., Inc.
    Inventors: Akira Nakagawara, Atsushi Takatori